Drug Profile
Research programme: type 2 diabetes mellitus therapeutics - Mochida
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Mochida Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in Japan
- 15 May 2015 Research programme: type 2 diabetes mellitus therapeutics - Mochida is available for licensing in World as of 15 May 2015. http://www.mochida.co.jp/english/business/licensing.html
- 15 May 2015 Type-2 diabetes mellitus therapeutics are no longer licensed to Merck worldwide